Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKG2D CAR-NK + PD-1 mAb in Anaplastic Thyroid Cancer
NCT06856278Phase 2Not yet recruiting
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NKG2D CAR-NK in anaplastic thyroid carcinoma (ATC), sponsored by Zhejiang Provincial People's Hospital. Primary endpoint: Safety and tolerability at Day 56. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
NKG2D CAR-NK
03
Conditions
anaplastic thyroid carcinoma (ATC)
Beyond the preview
Go deeper on NCT06856278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06856278.